Pfizer $PFE upgraded We raise our target price by $4 to $43, 13.0x our 2022 EPS estimate, in line with PFE's 10-year historical forward P/E average. We keep our 2021 EPS estimate at $3.26 and our 2022's at $3.32. We continue to think PFE is well-placed to largely benefit from the massive Covid-19 vaccine demand globally throughout 2021. As we previously explained in our February 2021 thematic report Ready for your Booster Shot?, we think that with the emergence of more dangerous Covid-19 variants, there is an increasing chance that repeat vaccinations to boost efficacy will be necessary. Pfizer CEO Bourla mentioned on Friday that there may be a need for a third dose of their mRNA-based vaccine jointly developed with BioNtech after 6-12 months following the initial inoculation. PFE also asked for emergency use authorization of the vaccine for U.S. children 12-15 years of age, expanding the market opportunity, in our view. We do not expect any issues with the FDA authorization and anticipate it to take place sometime in Q2 2021.
News 
Market Data 
Discover 
